How greed and profit fueled one failed Alzheimer drug
Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...
medtechdive15h
Former FDA head Gottlieb calls for less regulation of certain AI tools
Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st Century Cures Act.
Time on MSN8d
Why Johnson & Johnson’s CEO Welcomes Scrutiny
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
The American Journal of Managed Care9h
Nipocalimab’s Promising Potential in Advancing gMG Care
For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...